drugset / Trial / NCT05053659
Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the correct dose and safety of combining two new cancer drugs, loncastuximab tesirine and venetoclax, as a treatment for relapsed or refractory B cell lymphoma.These drugs are used to treat some lymphomas, but have not yet been tested in combination for the treatment of lymphoma. The main goal of this study is to determine the safety of the combination.
Timeline
- Start
- 2022-06-20
- Primary completion
- 2026-11
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Loncastuximab Tesirine | Other / unclassified | 50 ug/kg | Intravenous |
| Subject | Loncastuximab Tesirine | Other / unclassified | 150 ug/kg | Intravenous |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |
| Subject | Venetoclax | Small molecule | 600 mg | Oral |
| Subject | Venetoclax | Small molecule | 800 mg | Oral |